Please login to the form below
Merck KGaA
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.
Keytruda combo outshines Opdivo in kidney cancer
The data sets Merck &Co up to steal market share away from it rival, and the firm has already has filed the combination with the FDA. ... There is another contender in the checkpoint inhibitor field which could play a role: Pfizer and Merck KGaA’s
Industry aghast as EU Parliament backs biosimilar rule change
In an open letter to European institutions, the president of the EFPIA trade body, Merck KGaA chairman and CEO Stefan Oschmann (below), says the EP’s provisions “diverge significantly from the
Advair generics and acquisitions to hit GSK in 2019
Earnings to decline as company transforms. GlaxoSmithKline yesterday demonstrated a new boldness in its business development, signing a multi-billion dollar alliance with Germany’s Merck on next-generation immunotherapy. ... acquisition of Tesaro and
BMS CEO tackles investor ‘frustrations’ on immuno-oncology
BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck ... And in the meantime, Opdivo/Yervoy’s lucrative position in
Keytruda hits survival targets in first-line kidney cancer
New data presented at ESMO congress. Merck &Co could steal the thunder of its German namesake Merck KGaA after reporting strong survival data for Keytruda in front-line renal cell carcinoma, ... MSD says Keytruda is the first anti-PD-1 drug to improve
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Medical Writer
-
Salary TBC
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
-
Digital Account Director
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
-
Project Manager/ Account Manager
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
Subscribe to our email news alerts
- Lighthouse Medical Commuications US appoints Lisa Druce as its new Managing Partner
- GW Pharma's cannabis-based medicine to be tested in dementia
- International Childhood Cancer Day 2019
- AZ says dropping MedImmune will help ‘streamline’ its R&D
- Merck puts prostate cancer firmly in Keytruda’s sights
- Biosimilar Herceptin helps Roche gain new Perjeta recommendation
PMHub
Consulting at McCann Health
We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...
Latest intelligence
- International Childhood Cancer Day 2019
- The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
- Immuno-oncology in 2019: the rapid evolution continues
- Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
- Mixing up Focus Groups
- A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Quick links
Infographics
